Policy Statements

Browse the full list of our regulatory comments and legislative testimony below, or filter by state or national to view our federal and state-based policy work.

Tuesday, February 13, 2024 | CA

On February 13, 2024, California Policy Director Bianca Blomquist testified before the Assembly Committee On Jobs, Economic Development and The Economy and Budget Subcommittee No. 5 to demonstrate the importance of equitable distribution of SSBCI dollars, and encourage the state’s continued investment in diverse technical assistance resources.
 

Thursday, February 8, 2024 | National
Attachment:

On February 8, Small Business Majority sent a letter to President Biden urging him to underscore the importance of continued investments in America's small business during his State of the Union Address.

Wednesday, February 7, 2024 | VA
Attachment:

Today, Public Policy Director, Awesta Sarkash, submitted a letter of support to the Virginia House Committee on Appropriations in support of HB 419, which would close the gap on childcare investments in the state. Prioritizing childcare, in all its forms, is an investment that will have greater returns for Virginians and small businesses alike. 

Thursday, February 1, 2024 | VA
Attachment:

On February 1, Small Business Majority's Virginia Council member Shirley Modlin, owner of 3D Design and Manufacturing LLC, testified before the Virginia House Labor and Commerce Committee in support of HB 570, legislation which would establish a Prescription Drug Affordability Board in Virginia. Passing this legislation would help address the high cost of prescription drugs, which places a burden on small businesses and their employees.

Wednesday, January 31, 2024 | National
Attachment:

On January 31, Small Business Majority Founder and CEO John Arensmeyer submitted a Request for Information response to the bicameral, bipartisan Congressional working group exploring actions to expand access to paid leave for all Americans. Our response includes detailed information about how access to paid family and medical leave impacts small businesses nationwide and our comments on the proposal of establishing a federal paid family and medical leave program.

Monday, January 29, 2024 | VA
Attachment:

On January 29, Small Business Majority's Public Policy Director Awesta Sarkash submitted testimony before the Virginia Senate Commerce and Labor Committee on legislation to create a Prescription Drug Affordability Board. The bill would protect small employers, employees and other stakeholders within the healthcare system, particularly as small businesses are struggling with thin margins and high healthcare costs.

Monday, January 29, 2024 | NM
Attachment:

On January 29, Small Business Majority's Public Policy Director Awesta Sarkash submitted a letter of support for HB 7, the Health Care Affordability Fund, to the New Mexico House Committee on Appropriations.  This legislation would keep funding levels constant for the Healthcare Affordability Fund, which would ensure the Fund could continue providing affordable coverage to our communities, particularly our small employers. 

Thursday, January 25, 2024 | VA

Today, Public Policy Director, Awesta Sarkash, submitted written testimony in support of HB 737, Paid Family and Medical Leave Insurance Program in Virginia. Ahead of the House Labor and Commerce Committee hearing, Awesta underscored the need for a state-run leave program, which would allow small businesses to offer a modernized and robust benefits package to their employees. 

Wednesday, January 24, 2024 | NM
Attachment:

On January 24, Public Policy Director Awesta Sarkash testified in front of the New Mexico House Health and Human Services Committee in support of HB 6, which would create a state-run paid family and medical leave program. 

Wednesday, January 24, 2024 | GA
Attachment:

On January 24, Small Business Majority's Georgia Director and National Women's Entrepreneurship Director, Rachel Shanklin, testified before the Senate Health and Human Services Committee in support of the Lowering Prescription Drug Costs for Patients Act. 

Pages